Model-Informed Dose Optimization of Spironolactone in Neonates and Infants
<b>Background/Objectives</b>: Spironolactone (SP) has been used off-label in pediatrics since its approval, but its use is challenged by limited pharmacokinetic (PK) data in adults and especially in children. <b>Methods</b>: Physiologically based pharmacokinetic (PBPK) models...
Saved in:
| Main Authors: | Amira Soliman, Leandro F. Pippa, Jana Lass, Stephanie Leroux, Valvanera Vozmediano, Natalia V. de Moraes |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/3/355 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Leveraging Omeprazole PBPK/PD Modeling to Inform Drug–Drug Interactions and Specific Recommendations for Pediatric Labeling
by: Amira Soliman, et al.
Published: (2025-03-01) -
Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in Female Pattern Hair Loss Treatment
by: Naglaa Mohamed El Sayed, et al.
Published: (2025-01-01) -
Effect of spironolactone on monocyte subsets in atrial fibrillation: IMPRESS-AF randomised controlled trial
by: Farhan Shahid, et al.
Published: (2025-07-01) -
Middle‐Out Physiologically Based Pharmacokinetic Modeling to Support Pediatric Dosing Recommendation for Alectinib
by: Tamara vanDonge, et al.
Published: (2025-06-01) -
Low Risk of Hypotension in Women Treated with Spironolactone for Hair Loss
by: Rachel C Hill, et al.
Published: (2025-07-01)